Safety and Efficacy of AGN 203818 for Pain Associated With Fibromyalgia Syndrome

Phase 2

Terminated

• Conditions: Fibromyalgia
• Interventions: Drug: AGN 203818; Drug: placebo

• Registration Number: NCT00445705
• Lead Sponsor: Allergan

Brief Summary

This study will explore the safety and effectiveness of different doses of AGN 203818 in treating the pain associated with fibromyalgia syndrome. The study is being conducted in 2 parts. Part A enrolled 211 pts dosed with either 3, 20, 60 mg BID AGN 203818 or placebo over 4 week treatment duration. Part B will enroll 440 pts and dose with either 20, 100, 160 mg BID AGN 203818 or placebo over 12 week treatment duration.

Detailed Description

Not available

Study Timeline

• Study Start: 2007-03
• Study First Submitted: 2007-03-07
• Study First Submitted QC: 2007-03-07
• Study First Posted: 2007-03-09
• Primary Completion: 2008-01
• Study Completion: 2008-01
• Results First Submitted: 2011-12-16
• Results First Submitted QC: 2011-12-16
• Results First Posted: 2012-01-20
• Status Verified: 2015-08
• Last Update Submitted: 2015-08-25
• Last Update Posted: 2015-09-07

Recruitment & Eligibility

• Status: TERMINATED
• Sex: Female
• Target Recruitment: 211

Inclusion Criteria

• Diagnosis of fibromyalgia syndrome
• Moderate or severe pain associated with fibromyalgia

Read More

Exclusion Criteria

• Any other uncontrolled disease
• Pregnant or nursing females

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
AGN 203818 60 mg	AGN 203818	Part A: 60 mg AGN 203818 every 12 hours for 4 weeks
Placebo	placebo	Part A: Placebo every 12 hours for 4 weeks
AGN 203818 20 mg	AGN 203818	Part A: 20 mg AGN 203818 every 12 hours for 4 weeks
AGN 203818 3 mg	AGN 203818	Part A: 3 mg AGN 203818 every 12 hours for 4 weeks

Primary Outcome Measures

Name	Time	Method
Change From Baseline in Mean Daily-Average-Pain Score at Week 4	Baseline, Week 4	Change from Baseline in mean daily-average-pain score at week 4. Patients recorded their daily average pain on a 11-point scale (where 0 equals no pain and 10 equals worst pain imaginable) using a diary during the 4-week treatment period. A negative number change from baseline represents a decrease in average pain (improvement).

Secondary Outcome Measures

Name	Time	Method
Change From Baseline in the Short Form Brief Pain Inventory (SF-BPI) Average Pain Score at Week 4	Baseline, Week 4	Change from baseline in the SF-BPI average pain question score at week 4. The SF-BPI is a patient-rated questionnaire that assesses certain aspects of pain including location, intensity, and interference with certain daily activities. The "average pain" question was rated on an 11-point scale (where 0=no pain and 10=worst pain imaginable). A negative number change from baseline indicates a reduction in average pain.
Change From Baseline in the Fibromyalgia Impact Questionnaire (FIQ) Total Score of Physical Impairment at Week 4	Baseline, Week 4	Change from baseline in FIQ total score of physical impairment at week 4. The FIQ is a disease-specific questionnaire consisting of 10 questions and visual analog scales regarding functional disability, pain intensity, sleep function, stiffness, anxiety, depression, and overall sense of wellbeing. Each question is scored from 0 to 10 with 0 = no impairment (best) and 10 indicates maximum impairment (worst), for a minimum possible score (best) of 0 and a maximum possible (worst) total score of 100. A negative number change from baseline indicates improvement.
Patient Global Impression of Change (PGIC) for Fibromyalgia Syndrome Status at Week 4	Week 4	PGIC status for fibromyalgia syndrome at week 4. The PGIC consists of a self-evaluation by the patient of the overall change of their fibromyalgia syndrome since the beginning of the study, rated on a 7-point scale (score of 1-3 = very much improved to minimally improved; 4= no change; 5-7 = minimally worse to very much worse). Results are presented for the percentage of patients reporting each status: "improved"= score of 1-3; "no change"=score of 4; and "worse"=score of 5-7.